Beacon Equity Issues Trading Overview for Alpha Pro Tech Ltd.


DALLAS, Oct. 5, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Alpha Pro Tech Ltd. (AMEX:APT). The report includes financial and investment analysis and pertinent industry information you need to know to make an educated investment decision.

The investment report on Alpha Pro Tech Ltd. (AMEX:APT) should be of particular interest to comparable companies: Kimberly-Clark Corp. (NYSE:KMB), 3M Company (NYSE:MMM), Johnson & Johnson (NYSE:JNJ) and Cardinal Health Inc. (NYSE:CAH).

The report is available at: http://www.beaconequity.com/i/APT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Alpha Pro Tech Inc. (APT) engages in the development, manufacture and marketing of innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. The Company's products are grouped into three business segments: The Disposable Protective Apparel segment, the Building Supply segment and the Infection Control segment. The Company sells its products under the "Alpha Pro Tech" brand name and under a private label.

In the report, the analyst notes:

"Responding to a rise in demand, APT is ramping up production of its N95 respirator masks as the threat of the global H1N1 influenza continues to rise. The Company previously announced that it will triple N-95 respirator mask production starting in the beginning of the fourth quarter 2009, which begins October 1, 2009. . In the report, APT CEO Al Millar stated that the Company expects sales to continue to be much stronger than normal for the foreseeable future.

"Swine flu fears were further bolstered when the World Health Organization (WHO) warned on September 18 that the previously forecast annual swine flu vaccine production of 4.9 billion doses will be much lower than expected, though major pharmaceutical companies have shown that H1N1 vaccines are effective in one dose rather than the previously anticipated two-dose regimen."

To read the entire report visit: http://www.beaconequity.com/i/APT

BeaconEquity.com is one of the industry's largest small-cap report providers. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.



            

Mot-clé


Coordonnées

GlobeNewswire